Biogen (BIIB) Work In Process (2010 - 2018)
Biogen (BIIB) recorded quarterly Work In Process of $606.7 million in Q4 2018, little changed quarter-over-quarter from $605.7 million in Q4 2017, and little changed on a YoY basis from $605.7 million in Q4 2017.
Biogen (BIIB) Work In Process (2010 - 2018) Analysis & Trends
Biogen's Work In Process history runs 9 years deep, the most recent figure standing at $606.7 million for Q4 2018.
- In Q4 2018, Work In Process changed 0.17% year-over-year to $606.7 million; the TTM figure through Dec 2018 stood at $606.7 million (changed 0.17% YoY), while the FY2018 annual figure was $606.7 million, changed 0.17% from the prior year.
- Work In Process was $606.7 million for Q4 2018 at Biogen, roughly flat from $605.7 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $698.7 million in Q4 2016 to a low of $511.5 million in Q4 2014.
- Historically, Work In Process has averaged $600.0 million across 5 years, with a median of $605.7 million in 2017.
- The sharpest annual moves came in 2016 and 2017: Work In Process gained 20.97% in 2016, then declined 13.31% in 2017.
- A 5-year view of Work In Process shows it stood at $511.5 million in 2014, then increased by 12.92% to $577.6 million in 2015, then increased by 20.97% to $698.7 million in 2016, then slipped by 13.31% to $605.7 million in 2017, then grew by 0.17% to $606.7 million in 2018.
- The last three Work In Process figures came in at $606.7 million (Q4 2018), $605.7 million (Q4 2017), and $698.7 million (Q4 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 606.70 Mn |
| Dec 31, 2017 | 605.70 Mn |
| Dec 31, 2016 | 698.70 Mn |
| Dec 31, 2015 | 577.60 Mn |
| Dec 31, 2014 | 511.50 Mn |
| Dec 31, 2013 | 435.40 Mn |
| Mar 31, 2013 | 276.10 Mn |
| Dec 31, 2012 | 244.90 Mn |
| Jun 30, 2012 | 166.80 Mn |
| Mar 31, 2012 | 163.50 Mn |
| Dec 31, 2011 | 169.40 Mn |
| Dec 31, 2010 | 142.20 Mn |